Top 5 Performing Stocks To Invest In 2018

Apple Inc. (NSDQ:AAPL)hasn’t been having its own way recently. A few months ago, the company wasordered to return $13 billion in back taxes in Europe plus now it has todeal with a new US president in Donald Trumpwho clearly has reservationson how Apple runs its business affairs. Recently though, the Irish government announced that it would be appealing the European Commission’s decision to seek back taxes from the tech giant. However, with Trump now the president-elect,the Nasdaq index in general was performing very well until it sold off by over 150 points on Thursday the 10th of November and recovered marginally by 30 points on Friday, November 11th. Apple (and other tech stocks) got caught up in the downswing only to recover slightly which has left us now with Apple trading at just over $108.43 a share. Here’s Why Apple stock is cheap at sub $110.

Top 5 Performing Stocks To Invest In 2018: Equity Residential(EQR)

Advisors’ Opinion:


    Equity Residential (EQR), one of the biggest companies or components of the S&P 500 real estate index, owns 315 high-quality apartment properties in top U.S. growth markets, including Boston, New York, Washington, Seattle, San Francisco and Southern California.

  • [By Jim Powell]

    Steve Halpern: Another real estate position that you own is Equity Residential (EQR), which is a real estate investment trust. What’s your outlook for that?

Top 5 Performing Stocks To Invest In 2018: Take-Two Interactive Software, Inc.(TTWO)

Advisors’ Opinion:

  • [By Lee Jackson]

    Take-Two Interactive Software Inc. (NASDAQ: TTWO) saw the CFO at the video gaming company shedding shares this past week. Lainie Goldstein sold 56,167 shares at prices that ranged from $49.27 to $50.01. The total for the sale was posted at $3 million. The stocktraded on Friday at $47.90, so a well-timed sale indeed.

  • [By Danny Vena]

    With that much revenue at stake, what are the best gaming stocks for investors in 2017? Several companies have exhibited impressive performance over the past several years, and that trend is likely to continue. Top choices in the space includeActivision Blizzard, Inc. (NASDAQ:ATVI), Electronic Arts Inc. (NASDAQ:EA), and Take-Two Interactive (NASDAQ:TTWO).

  • [By Elizabeth Balboa]

    Other best performers of 2017 demonstrating long-term stability include Square Inc (NYSE: SQ), Alibaba Group Holding Ltd (NYSE: BABA), Universal Display Corporation (NASDAQ: OLED), NVIDIA Corporation (NASDAQ: NVDA) and Take-Two Interactive Software Inc (NASDAQ: TTWO).

  • [By Emily Stewart]

    Paulson purchased one million shares of Take-Two Interactive Software (TTWO) last quarter. As of the end of the period, the stake is worth $37.9 million.

    Take-Two Interactive is a developer, marketer and publisher of interactive entertainment for consumers around the globe. The company develops and publishes products through its two wholly owned labels: Rockstar Games and 2K. It has a $3.6 billion market cap and trades at a P/E of 165.16. 

  • [By ]

    I’m talking about returns of 31%, 35%, and more — all in a matter of weeks rather than months or years. In fact, we recently closed a trade on Take-Two Interactive (Nasdaq: TTWO) for a clean 38.9% in just over four weeks.

  • [By ]

    Satiating The Digital Desire
    Unlike generations before them, today’s kids looks to digital games and content played on consoles and their smart devices to entertain them. With a limited number of quality game producers and this quickly growing audience, I believe Take-Two Interactive Software (Nasdaq: TTWO) is poised for another leg higher.

Top 5 Performing Stocks To Invest In 2018: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) tumbled to the bottom of the S&P 500 today after the company’s CEO and CFO left the firm following the delay of its 10-Q last month.

    Getty Images

    Alexion Pharmaceuticals dropped 13% to $115.04 today, while the S&P 500 dipped 0.1% to 2,256.96.

    BMO’s M. Ian Somaiya offers his take on the chaos at Alexion:

    Alexion has delayed its 3Q 10-Q filing as a result of an internal investigation involving the company’s sales practices. The company continues to believe restatement of previously reported results is not required.Alexion expects filing of 3Q 10-Q in January 2017 or earlier, and 4Q/FY2016 earnings in February, when guidance is expected.

    Near-term downside may be priced in, caution on guidance. We believe the announcement of new management adds a new overhang to the stock, but also believe downside may be priced in (Alexion is down ~9% at open) and may provide an opportunity for investors to dip their toes if not their feet. We believe Alexion’s recovery will be driven by its next-generation C5 inhibitor, ALXN-1210, as every-eight-week dosing should enable Alexion to maintain 75% of the PNH market, while SubQ success, depending on dosing schedule/volume, may enable Alexion to do better. Additionally, we believe label extensions for Soliris in rMG, NMO may provide near-term growth drivers. Further upside is dependent on 30 pre-clinical assets in Alexion’s pipeline and the pace of Soliris adoption in MG. We believe the weakness may provide a unique opportunity for accumulation, with potential downside risk related to guidance from new management during 4Q/FY2016 earnings in February.

    Alexion Pharmaceuticals’ market capitalization fell to $25.8 billion today from $29.6 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) soared to the top of the S&P 500 today after its audit committee found no need to restate the company’s financials.

    Agence France-Presse/Getty Images

    Alexion Pharmaceuticalsgained 9.5% to $139.18 today, while the S&P 500 dipped 0.1% to 2,269.00.

    Morgan Stanley’sMatthew Harrison and team argue that the audit committees report is “lifting a cloud” over Alexion, but they still have their concerns:

    Without significant fireworks mgt. has filed the 10-Q lifting a cloud around the details on the potential wrong doing and its impact. While the “pull-in” sales had less than a 1% impact and do not appear pervasive in use as evidenced by the limited amount outside of 4Q15, we do wonder how the increased scrutiny will impact the selling organization and the potential increased conservatism among personnel going forward. We look forward to 2017 guidance and updates to MG filing and 1210 enrollment at the 4Q16 call.

    Alexion’s market capitalization rose to $31.2 billion today from $28.5 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By Johanna Bennett]

    Alexion Pharmaceuticals (ALXN), a drug maker focused on rare diseases, ended Thursday at the top of the list of the best performing stocks in the S&P 500 index.

    The shares climbed almost 3.3%, or $3.78, to close at $118.35, compared to the S&P 500, which fell almost 16 points, or 0.7% to end at 2,328.95.

    Its been a rough two years for Alexion. Since mid-2015, when the stock traded above $200, shares have tumbled on worries about the durability of its main drug Soliris, political furor over high drug prices, and the abrupt departure of two top executives amid an investigation into sales practices.

    The shares are down more than 3% since the start of 2017.

    Solaris sales will be a focus next week when Alexion reports first quarter financial results. Earlier today, Barclays reiterated an overweight rating on the stock and a $115 price target, but raised its 2018 and 2019 earnings estimates, arguing that rivals are unlikely to significantly challenge either Solaris or the experimental drug ALXN1210.

    …we are increasingly comfortable with the Soliris outlook and now forecast 2021E sales at $4.8B vs. our previous $4.6B, which is +5% ahead of consensus. Weve raised 2017 and 2018 adjusted EPS estimates by $0.05 and $0.10 respectively. Our 5-year revenue CAGR increases by +70 bps to 14.7% while EPS growth has improved by +100 bps to 20.0%, near the top of the peer group.

    Barrons weighed in on Alexion in February, which has been bandied about as a takeout candidate. We have argues

    Earlier this week, Credit Suisse analysts listed Alexion as one of three biotech stocks that will steal the spotlight during earnings season.

  • [By Chris Lange]

    Shares of Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) saw a solid gain on Thursday after the firm announced positive results from its late-stage trial of ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). One analyst even took this opportunity to weigh in on the stock.

  • [By Paul Ausick]

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $102.47 on Tuesday, down more than 11% compared with Monday’s closing price of $115.42. The stock’s 52-week high is $157.02. Volume totaled more than 16 million shares, nearly 6 times the daily average of about 3 million. The company announced several executive changes this morning.

Top 5 Performing Stocks To Invest In 2018: BP Prudhoe Bay Royalty Trust(BPT)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, energy shares fell by 1.30 percent. Meanwhile, top losers in the sector included BP Prudhoe Bay Royalty Trust (NYSE: BPT), down 14 percent, and Gulf Island Fabrication, Inc. (NASDAQ: GIFI), down 13 percent.


    Our featured recommendation, the BP Prudhoe Bay Royalty Trust (BPT), is a grantor trust. What that means is that the trust holds royalty interest in minerals from the Prudhoe Bay on the North Slope of Alaska.

Top 5 Performing Stocks To Invest In 2018: MGE Energy Inc.(MGEE)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, utilities shares fell by 0.75 percent. Meanwhile, top losers in the sector included California Water Service Group (NYSE: CWT), down 7 percent, and MGE Energy, Inc. (NASDAQ: MGEE), down 6 percent.

Leave a Reply

Your email address will not be published. Required fields are marked *